A Phase 4, Double-blind, Randomised, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa
Phase of Trial: Phase IV
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms SHARPS
- Sponsors AbbVie
- 02 Nov 2017 Planned End Date changed from 19 Jan 2020 to 18 Sep 2019.
- 02 Nov 2017 Planned primary completion date changed from 2 Oct 2019 to 18 Sep 2019.
- 19 Jul 2017 Planned End Date changed from 1 Feb 2020 to 19 Jan 2020.